Maravai LifeSciences Holdings Inc Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)0.71 Intrinsic Value $6.15median of 2 methodsbased on filings through 30 Jun 2026 Market Price $7.50Price as of 1 Oct 2026 OvervaluedIntrinsic value is 18% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $2.8B Enterprise Value $2.9B Shares Outstanding 370.4M diluted Next Earnings Date5 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Maravai LifeSciences is navigating a critical transition period following the post-pandemic collapse of COVID-related demand. While the company has successfully executed a major restructuring program—removing over $65 million in costs and returning to positive Adjusted EBITDA and free cash flow in Q1 2026—its long-term growth remains highly dependent on the clinical and commercial success of its customers' non-COVID mRNA, cell, and gene therapy programs. Although proprietary technologies like CleanCap provide a strong competitive moat in a high-growth niche, the company's narrow customer base and high concentration risk relative to diversified life sciences giants warrant a cautious Hold rating until sustained non-COVID revenue acceleration is established. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$6.50 Mean target$7.30 High · most bullish analyst$8.00 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $6.50 Slower-than-expected adoption of non-COVID mRNA pipelines, clinical trial failures among key customers, or intense competition from larger diversified tools providers limits base business growth, causing margins to compress. Base CaseCentral scenario $7.30 Matches the consensus meanMaravai achieves its raised full-year 2026 guidance of $205M to $215M in revenue and $30M to $32M in Adjusted EBITDA, supported by steady 10-15% growth in its base TriLink and Cygnus segments, while maintaining positive free cash flow. Bull CaseUpside scenario $8.00 Rapid clinical advancement and commercial approvals of non-COVID mRNA therapeutics utilizing CleanCap technology drive outsized demand, leading to high-margin revenue growth that exceeds the raised 2026 guidance. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |